Volume 1.38 | Oct 8

Prostate Cell News 1.38, October 8, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

New Nanoparticles Could Improve Cancer Treatment 
In recent years, studies have shown that for many types of cancer, combination drug therapy is more effective than single drugs. However, it is usually difficult to get the right amount of each drug to the tumor. Now researchers have developed a nanoparticle that can deliver precise doses of two or more drugs to prostate cancer cells. [Press release from the Massachusetts Institute of Technology discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN HOW STEMCELL Technologies Inc
 



SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]



SCIENCE NEWS

Novel Test Following Prostate Surgery Could Detect Cancer Recurrence Earlier
A new test could reliably detect early increases in prostate specific antigen levels in men who have undergone prostate cancer-treating surgery. [Press release from the American Association for Cancer Research (AACR) discussing data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Engineering of Self-Assembled Nanoparticle Platform for Precisely Controlled Combination Drug Therapy
Researchers describe a self-assembled polymeric nanoparticle platform to target and control precisely the codelivery of drugs with varying physicochemical properties to cancer cells. [Proc Natl Acad Sci USA]

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
This study investigates the contribution of microtubules and the cytoskeleton to androgen-mediated signaling and the consequences of their inhibition on androgen receptor activity in human prostate cancer. [Cancer Res]

IFN Induces miR-21 Through a Signal Transducer and Activator of Transcription 3-Dependent Pathway as a Suppressive Negative Feedback on IFN-Induced Apoptosis
Here, researchers report that the cytokine IFN rapidly induces miR-21 expression in human and mouse cells. Signal transducer and activator of transcription 3 (STAT3) was implicated in this pathway based on the lack of IFN effect on miR-21 expression in prostate cancer cells with a deletion in the STAT3 gene. [Cancer Res]

Integration of Cap Analysis of Gene Expression and Chromatin Immunoprecipitation Analysis on Array Reveals Genome-Wide Androgen Receptor Signaling in Prostate Cancer Cells
In this study, researchers performed 5′-cap analysis of gene expression to determine androgen-regulated transcription start sites and chromatin immunoprecipitation on array (ChIP-chip) analysis to identify androgen receptor binding sites and histone H3 acetylated sites in the human genome. [Oncogene]

Genome-Wide Analysis of Androgen Receptor Binding and Gene Regulation in Two CWR22-Derived Prostate Cancer Cell Lines
In this study, researchers investigated androgen receptor (AR) binding and AR-dependent transcription in two related castrate-resistant cell lines derived from androgen-dependent CWR22-relapsed tumors: CWR22Rv1 (Rv1) and CWR-R1 (R1). [Endocr Relat Cancer]

Effect of the Modulation of Leucine Zipper Tumor Suppressor 2 Expression on Proliferation of Various Cancer Cells Functions as a Tumor Suppressor
Researchers showed that NF-kappaB-induced modulation of beta-catenin/Tcf pathway is regulated by lzts2 expression in mesenchymal stem cells and several cancer cells, and that NF-kappaB-induced lzts2 expression is differentially regulated among cancer cell types. [Mol Cell Biochem]

CLINICAL RESEARCH

Quality-of-Life Impact of Primary Treatments for Localized Prostate Cancer in Patients Without Hormonal Treatment
The objective of this study was to compare the quality of life impact of the three most common primary treatments on patients who were not receiving adjuvant hormonal treatment. [J Clin Oncol]

Nuclear Androgen Receptor Staining in Bone Metastases is Related to a Poor Outcome in Prostate Cancer Patients
Serum prostate-specific antigen (PSA) at metastasis surgery, although related to outcome, was not associated with androgen receptor staining, markers of metastasis growth or PSA staining in metastases. [Endocr Relat Cancer]

Gemcitabine and Docetaxel in Metastatic, Castrate-Resistant Prostate Cancer
In a phase II study of combined docetaxel and gemcitabine, the authors assessed its safety and activity in patients with chemotherapy-naive, metastatic castrate-resistant prostate cancer. [Cancer]



INDUSTRY NEWS

New Data for Erbitux in Prevalent Cancers to be Revealed at ESMO
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces that it will be presenting new data from several studies of Erbitux® (cetuximab) in a range of solid tumor types – including the first Phase II data in breast and prostate cancers. [Merck Serono Press Release]

Optical Imaging System to Help Detect Prostate Cancer
A bioengineering professor has landed a three-year, $958,660 grant from the National Institutes of Health to investigate a minimally invasive way to screen for and diagnose prostate cancer by using a multi-channel optical imaging system. [University of Texas at Arlington Press Release]

Vanderbilt Wins CHOICE Award for Prostate Cancer Research
Vanderbilt-Ingram Cancer Center has received a $7.6 million American Recovery and Reinvestment Act of 2009 (ARRA) stimulus grant to coordinate a study comparing the effectiveness of various treatments for prostate cancer. [Vanderbilt University Medical Center Press Release]

Teva and OncoGenex Announce Initiation of Second Phase III Trial of Custirsen in Men with Metastatic Prostate Cancer
Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced the initiation of SYNERGY, a global Phase III trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer. [Teva Pharmaceuticals Industries Ltd. Press Release]

STEMSOFT Connect – A Simplified Solution to a Complex Problem
STEMSOFT Software Inc. is pleased to announce the release of their new standard interfaces, STEMSOFT Connect(TM). [STEMSOFT Software Inc. Press Release]


POLICY NEWS

NIH Grants Will Advance Studies of the Form and Function of Proteins
The National Institutes of Health has awarded 23 grants for structural biology research totaling up to $290 million over five years. [National Institutes of Health, United States]

NCBI Launches the Database of Genomic Structural Variations
The National Institutes of Health announced the launch of a new resource, called the Database of Genomic Structural Variation, or dbVar, to help scientists understand how differences in DNA contribute to human health and disease. [National Institutes of Health, United States]

Lawmakers Introduce Bipartisan Legislation to Create Jobs and Promote Investment in Life Sciences
U.S. Representatives introduced bipartisan legislation that will provide tax incentives for small and mid-sized businesses to invest in life sciences research and development on a targeted basis. The Life Sciences Jobs and Investment Act of 2010 provides an opportunity to enhance medical innovation, life sciences education and job creation in the United States. [House of Representatives, United States]

NIH and FDA Announce Awards to Advance Regulatory Science
The National Institutes of Health will award $9.4 million over three years to support four research projects in regulatory science. This research is conducted in partnership with the U.S. Food and Drug Administration, which will contribute approximately $950,000. [National Institutes of Health, United States]

Tumor Microenvironment Network (TMEN) (U54) (RFA-CA-10-021) [Department of Health and Human Services, United States]

Resource Related Research Projects for Development of Animal Models and Related Materials (R24) (PAR-10-289) [National Center for Research Resources, United States]

Animal and Biological Material Resource Centers (P40) (PAR-11-001) [National Center for Research Resources, United States]

NHLBI Translational Research Implementation Program (TRIP) – Limited Competition – (P50) (RFA-HL-12-003) [National Heart, Lung, and Blood Institute, United States]

Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-24548) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-24680) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-24549) [National Institutes of Health, United States]



EVENTS (Listed by Date)

American Association for Cancer Research (AACR) Translational Cancer Research for Basic Scientists
October 17-22, 2010
Boston, United States

6th Modern Drug Discovery & Development Summit (M3D)
October 20-22, 2010
San Francisco, United States

American Institute for Cancer Research (AICR) 2010 Annual Cancer Research Conference
October 21-22, 2010
Washington, DC, United States

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

Select Biosciences 3rd Annual Molecular Diagnostics World Congress
October 28-29, 2010
San Diego, United States

UAE Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

Cancer Pharmacogenetics: Personalizing Medicine
November 22-24, 2010
Madrid, Spain

11th Annual Meeting of the Society of Urologic Oncology (SUO) Extraordinary Opportunities for Discovery
December 8-9, 2010
Bethesda, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

MENA Oncology Conference
March 11-12, 2010
Cairo, Egypt

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

National Cancer Institute (NCI) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Cell Therapy Technologist (Opexa Therapeutics)

Clean Room Team Leader – Cellular Therapy (Cell Medica Limited)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost.
Visit here to post your career opportunities.


Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us